DM1

DAUNOMYCIN

Created: 1999-07-08
Last modified:  2020-06-05

Find related ligands:

Chemical Details

Formal Charge0
Atom Count67
Chiral Atom Count6
Bond Count71
Aromatic Bond Count12
2D diagram of DM1

Chemical Component Summary

NameDAUNOMYCIN
SynonymsDAUNORUBICIN
Systematic Name (OpenEye OEToolkits)(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
FormulaC27 H29 N O10
Molecular Weight527.52
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs10.04O=C2c1c(O)c5c(c(O)c1C(=O)c3cccc(OC)c23)CC(O)(C(=O)C)CC5OC4OC(C(O)C(N)C4)C
SMILESCACTVS3.341COc1cccc2C(=O)c3c(O)c4C[C](O)(C[CH](O[CH]5C[CH](N)[CH](O)[CH](C)O5)c4c(O)c3C(=O)c12)C(C)=O
SMILESOpenEye OEToolkits1.5.0CC1C(C(CC(O1)OC2CC(Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)C)O)N)O
Canonical SMILESCACTVS3.341 COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O
Canonical SMILESOpenEye OEToolkits1.5.0 C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)C)O)N)O
InChIInChI1.03 InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
InChIKeyInChI1.03 STQGQHZAVUOBTE-VGBVRHCVSA-N

Drug Info: DrugBank

DrugBank IDDB00694 
NameDaunorubicin
Groups approved
DescriptionA very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Synonyms
  • Rubidomycin
  • (+)-Daunomycin
  • Acetyladriamycin
  • Daunorubicine
  • Daunorubicin liposomal
Brand Names
  • Vyxeos Liposomal
  • Daunorubicin Hydrochloride Injection
  • DaunoXome
  • Daunoxome Liposomal - IV 2mg/ml, 50mg/vial
  • Daunorubicin Injectable Solution
IndicationFor remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Daunorubicin is indicated in combination with [cytarabine] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]
Categories
  • Anthracycline Topoisomerase Inhibitor
  • Anthracyclines
  • Anthracyclines and Related Substances
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
ATC-Code
  • L01DB02
  • L01XY01
CAS number20830-81-3

Drug Targets

NameTarget SequencePharmacological ActionActions
DNA-unknownintercalation
DNA topoisomerase 2-alphaMEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTY...unknowninhibitor
DNA topoisomerase 2-betaMAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLS...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate,inhibitor
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknowninducer
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL178
PubChem 30323
ChEMBL CHEMBL178
ChEBI CHEBI:41977
CCDC/CSD DAUNMY